What's New

News

2018/08/20
Nippon Kayaku launches Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK”, a humanized anti-human HER2 monoclonal Antibody
2018/03/23
Nippon Kayaku Receives Manufacture and Marketing Approval in Japan for Biosimilar of Trastuzumab Monoclonal Antibody
2017/09/28
Updated information of CSR
2017/08/31
Nippon Kayaku announces the final data analysis of a global phase 3 study of NK105, a novel macromolecular micelle encapsulating an anticancer drug, will be presented at the ESMO 2017 Congress
2017/04/26
Agreement on major articles of contract for collaboration for CT-P10, in Japan
2017/04/11
Submission of Application for Marketing Approval of CT-P6 Trastuzumab Biosimilar Monoclonal Antibody in Japan
2016/09/30
Updated information of CSR
2016/07/05
Results of Phase III study of NK105, a novel macromolecular micelle encapsulating an anticancer drug
2016/06/08
Announcement: Establishment of Joint Venture Company for MAB Production
2016/06/06
Notice Concerning Monthly Share Repurchase Results and Repurchase Completion
2016/06/05
The 100th anniversary of the Nippon Kayaku Group’s founding is on June 5, 2016.
2016/04/27
Nippon Kayaku Announces FDA Orphan Drug Designation to New Polymeric micelle Anti-Cancer Drug NK012 for Small Cell Lung Cancer
2016/03/30
We have published "Nippon Kayaku Commemorating 100 Years of Sukima Ideas".
2015/11/10
Nippon Kayaku Announces License Agreement with Eiger BioPharmaceuticals to Develop BestatinTM (ubenimex) for Inflammatory Diseases Involving LTB4
2015/10/06
Updated information of CSR
2015/10/05
Maintenance notification
2015/07/30
Nippon Kayaku Announces Start-up Clinical Trial in Japan as the part of Global Phase 3 Clinical Trial Program for CT-P6 in Breast Cancer
2015/06/08
Management Changes (Appointments & Transfers)
2015/04/21
We have published CSR Procurement.
2015/03/31
Nippon Kayaku is pleased to announce that the English version of its corporate website has been revamped and an all new Chinese version has been published.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR